Gilenya (fingolimod) 0.5 mg daily for the treatment of relapsing forms of MS by the Food and Drug Administration approved. A group Novartis, the Swiss drugmaker Gilenya is the first drug by mouth for the treatment of relapsing forms of multiple sclerosis (MS) in the United States, pointed out – it reduces the frequency of attacks of MS, and taken to a slowdown in the accumulation of some physical problems with MS Multiple possible.
Clinical trials showed patients with the study subjects, 2600 the safety and good endurance, and said Norvartis. Some of the respondents in the seventh year Gilenya treatment.
Others are not far behind: the Food and Drug Administration (FDA) Advisory Committee recommended unanimously approved Gilenya in June, with work scheduled to be held in September, while the drug is also before, the European Medicines Agency and other worldwide. Gilenya health, and on the Novartis said with a new highly effective treatment option in patients who suffer from the comfort of capsule once daily by mouth intended to be launched in Russia next year early. It is used to treat relapsing forms of MS ofmultiple use, with nearly 85% of patients with multiple sclerosis believe this early form of the disease, Novartis said.
0 comments:
Post a Comment